ARS Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. ARS is a development-stage biopharmaceutical company focused on neffy, a needle-free intranasal epinephrine product. It had no approved products or product-sale revenue during the quarter.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Collaboration revenue | $0 | $20,000 | Down $20,000 |
| Research and development expense | $5.2 million | $6.6 million | Down 20% |
| General and administrative expense | $8.0 million | $12.2 million | Down 35% |
| Total operating expenses | $13.2 million | $18.7 million | Down 30% |
| Other income, net | $2.9 million | $3.8 million | Down 23% |
| Net loss | $10.3 million | $15.0 million | Loss narrowed 31% |
| Net loss per share | $0.11 | $0.16 | Loss per share narrowed |
| Net cash used in operating activities | $6.7 million | $12.4 million | Cash use decreased |
- Margins: Product gross margin is not applicable; the company had no product sales.
- Cash and investments: $223.6 million at March 31, 2024, comprising $56.0 million in cash and cash equivalents and $167.6 million in short-term investments. The combined balance was $228.4 million at December 31, 2023.
- Balance sheet: Total assets were $227.6 million, total liabilities $3.7 million, and stockholders’ equity $223.9 million. No debt is reported on the March 31 balance sheet; current and long-term liabilities primarily comprise payables, accruals, and lease obligations.
- Cash flow: Investing activities used $8.5 million, mainly reflecting net purchases of short-term investments; financing activities provided $0.3 million from option exercises. Cash and cash equivalents declined $15.0 million during the quarter.
- Accumulated deficit: $141.6 million. Stock-based compensation expense was $3.3 million, up from $2.3 million a year earlier.
Material changes versus prior year
- Operating expenses fell $5.5 million. R&D decreased $1.3 million, principally from lower device-development costs, partly offset by higher clinical-trial costs. G&A decreased $4.2 million, mainly because pre-commercial launch activity was lower.
- Other income declined $0.9 million, primarily due to lower interest income and the absence of a 2023 gain from a sale of in-process research and development.
- Operating cash use decreased $5.7 million. Investing cash use was substantially lower than in Q1 2023, when the company made much larger net purchases of short-term investments.
Outlook, commentary, and risks
- FDA: ARS submitted its response to the neffy Complete Response Letter in April 2024, after reporting topline results from the requested repeat-dose study. Management anticipated an FDA action date of October 2, 2024; approval was not assured. The FDA had also requested nitrosamine testing, and the company reported no measurable levels in its additional testing.
- Europe and development: ARS submitted a response to the EMA’s CHMP in April 2024 and expected an opinion in Q2 2024. It reported positive topline urticaria results and anticipated starting a Phase 2 outpatient study in the second half of 2024, with a potential pivotal study in 2025.
- Spending and runway: Management expected R&D expense to decrease in 2024 versus 2023 and G&A to remain broadly consistent, while expenses and losses could rise with approval preparation and commercialization. The financial-statement note says available funds cover anticipated needs for at least 12 months after issuance; MD&A estimates funding for at least three years under the current operating plan. Both are forecasts and subject to uncertainty.
- Key risks: The business depends on neffy, which has no commercial sales and remains subject to regulatory review. Commercial success also depends on market adoption, coverage and reimbursement, manufacturing and supply readiness, and the company’s ability to establish commercial capabilities. ARS relies on third parties for manufacturing and international development and commercialization.
- Patent contingencies: Amphastar’s appeal concerning U.S. Patent No. 10,682,414 and an opposition to a European patent remain unresolved. The company recorded no liability because any loss or range of loss could not be reasonably estimated. The filing describes the outcomes as uncertain.
- Other obligations and governance: The Recordati termination agreement includes potential future milestone and royalty payments. Related-party consulting expenses included $0.7 million in Q1 2024 for an entity owned by the CEO and his spouse, the CMO. Two executives adopted Rule 10b5-1 plans during the quarter covering planned sales of 40,000 and 50,000 shares, respectively.
Most important facts for investors to verify
- FDA and EMA decisions, their timing, and any additional information or studies regulators may require.
- Whether the company’s projected cash runway remains adequate as launch, manufacturing, and commercial spending develops.
- Commercial launch readiness, supply capacity, pricing, reimbursement, and early demand if neffy is approved.
- Developments in the U.S. patent appeal and European patent opposition, and any resulting impact on exclusivity or commercialization.
- Progress and costs of the urticaria program, international partner programs, and contingent payments under collaboration and termination agreements.